Why the study?
Metabolic syndrome is associated with low-grade inflammation that can be exacerbated by renal artery stenosis and renovascular hypertension, but whether mesenchymal stem/stromal cells could reduce fat inflammation in this setting remained unknown.
Does autologous adipose-derived MSC injection reduce fat inflammation in pigs with metabolic syndrome and renovascular hypertension?
Population
Twenty-four pigs
Comparison
Lean control vs MetS vs MetS + RAS vs MetS + RAS + MSCs
Design
Preclinical animal study
Follow-up
Four weeks
Key result
Autologous adipose-derived MSCs reduced pro-inflammatory cytokines, decreased fat fibrosis, and attenuated fat inflammation in pigs with metabolic syndrome and renovascular hypertension.
Authors
Loading...
MSCs reversed adipose inflammation in a porcine MetS+RAS model; leaves open translation to human cardiometabolic therapy.
Does autologous adipose-derived MSC injection reduce fat inflammation in pigs with metabolic syndrome and renovascular hypertension?
Autologous adipose-derived MSC therapy attenuates fat inflammation and improves metabolic outcomes in a porcine model of metabolic syndrome and renovascular hypertension.
Krueger et al. (2025) studied Metabolic syndrome and renovascular hypertension (n=24). Autologous adipose-derived mesenchymal stem/stromal cells (MSCs) vs. Lean (control), MetS, and MetS + RAS groups was evaluated on Fat volumes and inflammatory markers (MCP-1, TNF-a, IL-6). Autologous adipose-derived MSCs reduced pro-inflammatory cytokines, decreased fat fibrosis, and attenuated fat inflammation in pigs with metabolic syndrome and renovascular hypertension.